Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Studie for å identifisere og beskrive prediktive faktorer for tromboemboliske hendelser hos pasienter med høyrisiko polycytemi Vera (Prospero)

22. september 2026 oppdatert av: Novartis Pharmaceuticals

Prospektiv observasjonsstudie for å identifisere og beskrive prediktive faktorer for tromboemboliske hendelser hos pasienter med høyrisiko polycytemi Vera

This is a prospective observational study that will enroll patients with high-risk Polycythemia Vera (PV) with at least one Thromboembolic Event (TE) after diagnosis or up to 2 years prior to diagnosis.

This is a non-randomized study, and to ensure a sufficient number of patients in both cohorts, enrollment in each cohort will be terminated once the target of 150 patients has been reached.

Studieoversikt

Status

Aktiv, ikke rekrutterende

Forhold

Detaljert beskrivelse

All patients are already on treatment with hydroxyurea or ruxolitinib at enrollment as per clinical practice and independently of their participation in this study. In addition, the follow-up visits and the evaluation procedures required in the study protocol correspond to current clinical practice. According to local regulations related to observational studies, assessments such as blood tests are justified by the purpose and rationale of the study (i.e., the identification of possible predictive factors of TEs) and are considered current clinical practice. Data related to other procedures will be collected only if such procedures are performed as per clinical practice but are not required otherwise.

Patients in both cohorts will be followed for 3 years after enrollment and will have visits at Months 6, 12, 18, 24, 30 and 36. A time window of ± 1 month is permitted for all visits.

Studietype

Observasjonsmessig

Registrering (Faktiske)

242

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

      • Naples, Italia, 80131
        • Novartis Investigative Site
    • AL
      • Alessandria, AL, Italia, 15121
        • Novartis Investigative Site
    • AN
      • Ancona, AN, Italia, 60020
        • Novartis Investigative Site
    • BA
      • Bari, BA, Italia, 70124
        • Novartis Investigative Site
    • BO
      • Bologna, BO, Italia, 40138
        • Novartis Investigative Site
    • CO
      • Como, CO, Italia, 22100
        • Novartis Investigative Site
    • CS
      • Cosenza, CS, Italia, 87100
        • Novartis Investigative Site
    • CT
      • Catania, CT, Italia, 95123
        • Novartis Investigative Site
    • FI
      • Florence, FI, Italia, 50134
        • Novartis Investigative Site
    • GE
      • Genova, GE, Italia, 16132
        • Novartis Investigative Site
    • LE
      • Lecce, LE, Italia, 73100
        • Novartis Investigative Site
      • Tricase, LE, Italia, 73039
        • Novartis Investigative Site
    • MB
      • Monza, MB, Italia, 20900
        • Novartis Investigative Site
    • MI
      • Milan, MI, Italia, 20122
        • Novartis Investigative Site
    • PA
      • Palermo, PA, Italia, 90127
        • Novartis Investigative Site
      • Palermo, PA, Italia, 90146
        • Novartis Investigative Site
    • PC
      • Piacenza, PC, Italia, 29121
        • Novartis Investigative Site
    • PD
      • Padova, PD, Italia, 35128
        • Novartis Investigative Site
    • PI
      • Pisa, PI, Italia, 56126
        • Novartis Investigative Site
    • PR
      • Parma, PR, Italia, 43126
        • Novartis Investigative Site
    • RC
      • Reggio Calabria, RC, Italia, 89124
        • Novartis Investigative Site
    • RE
      • Reggio Emilia, RE, Italia, 42123
        • Novartis Investigative Site
    • RM
      • Roma, RM, Italia, 00168
        • Novartis Investigative Site
      • Roma, RM, Italia, 00161
        • Novartis Investigative Site
      • Roma, RM, Italia, 00189
        • Novartis Investigative Site
    • SA
      • Pagani, SA, Italia, 84016
        • Novartis Investigative Site
    • TO
      • Orbassano, TO, Italia, 10043
        • Novartis Investigative Site
      • Torino, TO, Italia, 10126
        • Novartis Investigative Site
    • TR
      • Terni, TR, Italia, 05100
        • Novartis Investigative Site
    • VA
      • Varese, VA, Italia, 21100
        • Novartis Investigative Site
    • VI
      • Vicenza, VI, Italia, 36100
        • Novartis Investigative Site
    • VR
      • Verona, VR, Italia, 37134
        • Novartis Investigative Site
    • VT
      • Viterbo, VT, Italia, 01033
        • Novartis Investigative Site

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 99 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

The study will involve patients in Italy with high-risk Polycythemia Vera

Beskrivelse

Inclusion Criteria:

  1. Signed informed consent must be obtained prior to participation in the study.
  2. Age ≥18 years.
  3. Diagnosis of PV according to WHO 2008 or WHO 2016 and high-risk stratification according to European LeukemiaNet (ELN) classification.
  4. At least one TE after diagnosis or up to 2 years prior to diagnosis.
  5. Patients on treatment with hydroxyurea at enrollment and for at least 18 months prior to enrollment or those on treatment with ruxolitinib who started treatment up to 18 months before enrollment.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Observasjonsmodeller: COHORT
  • Tidsperspektiver: PROSPECTIVE

Kohorter og intervensjoner

Gruppe / Kohort
Intervensjon / Behandling
Hydroxyurea

Patients being treated with hydroxyurea at enrollment and for at least 18 months prior to enrollment. Patients may switch to ruxolitinib treatment during the study in case of inadequate response or intolerance.

Prospective observational study. There is no treatment allocation. Patients prescribed with Hydroxyurea are eligible to enroll into this study.

Ruxolitinib

Patients on treatment with ruxolitinib who started treatment up to 18 months prior to enrollment.

Prospective observational study. There is no treatment allocation. Patients prescribed with Ruxolitinib are eligible to enroll into this study.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Percentage of abnormalities presented in patients with Thromboembolic Events (TEs) during the follow up
Tidsramme: Up to 36 months

Demographics, blood pressure, laboratory blood tests, and use of antiplatelets and/or anticoagulants are predictors of TE occurrence, a univariate Cox regression model for repeated events will be applied for each predictor considering all the TEs occurring within 12 months and the time from baseline to each occurrence. Predictors found statistically significant at the 5% level will then be considered in a multivariate Cox regression model for repeated events.

Up to 36 months
Blood pressure
Tidsramme: Up to month 36

Blood pressure is going to be collected

Up to month 36
Number of patients with abnormal Body Mass Index (BMI)
Tidsramme: Up to month 36

Number of patients with abnormal Body Mass Index (BMI) will be collected

Up to month 36
Number of patients with abnormal weight
Tidsramme: Up to month 36

Number of patients with abnormal weight will be collected

Up to month 36
Number of patients with abnormal Neutrophil (NEP) count
Tidsramme: Up to 36 months

Number of patients with abnormal Neutrophil (NEP) count will be collected

Up to 36 months
Number of patients with abnormal White blood Count (WBC)
Tidsramme: Up to 36 months

Number of patients with abnormal White blood Count (WBC) will be collected

Up to 36 months
Number of patients with abnormal Lymphocytes (LYP) count
Tidsramme: Up to 36 months

Number of patients with abnormal Lymphocytes (LYP) count will be collected

Up to 36 months
Number of participants using antiplatelets and/or anticoagulants on the incidence of TEs
Tidsramme: Up to 36 months

Number of participants using antiplatelets and/or anticoagulants on the incidence of Thromboembolic Events (TEs) will be collected

Up to 36 months

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Synergistic combinations of predictive factors
Tidsramme: Up to 36 months

Synergistic combinations of predictive factors (Red cell Distribution Width, neutrophils, lymphocytes, neutrophil/ lymphocyte ratio and platelets).

Synergy score is defined as the product of the individual significances of variable 1 and 2 (expected) divided by the significance of the two-variable model (observed) To investigate cases of extreme synergy, instances in which two variables split the given cohort into high-risk and low-risk patients are far better than either variable alone. A simple synergy scoring metric to rank variable in terms of synergy (S):S12=(P1*P2)/P12 where P1 and P2 are the maximum possible (Cox regression derived) p-values for variable 1 and variable 2 and P12 was the max. p-value possible from the combination of variables 1 and 1. This synergy is intended to capture a variable that may provide exclusive non-redundant information when attempting to split a cohort based on risk and may provide an added insight into the functional/clinical rationale of a model

Up to 36 months
Yearly incidence of TEs
Tidsramme: 36 months

Yearly incidence of Thromboembolic Events (TEs) will be collected

36 months
Incidence of arterial and venous TEs in the hydroxyurea and ruxolitinib cohorts
Tidsramme: 36 months

Incidence of arterial and venous TEs in the hydroxyurea and ruxolitinib cohorts will be collected

36 months
Incidence and severity of adverse events
Tidsramme: 36 months

Incidence and severity of adverse events according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0.

36 months

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Studieleder: Novartis Pharmaceuticals, Novartis Pharmaceuticals

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

2. mars 2023

Primær fullføring (Antatt)

31. august 2027

Studiet fullført (Antatt)

31. august 2027

Datoer for studieregistrering

Først innsendt

16. september 2022

Først innsendt som oppfylte QC-kriteriene

16. september 2022

Først lagt ut (Faktiske)

21. september 2022

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

25. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

22. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere